{"ticker": {"uuid": "660f60ee-84e7-4a1e-97e8-2fea191df290", "symbol": "DXR", "name": "Daxor Corporation", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Instruments & Supplies"}, "articles": [{"title": "Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPWUhyalVTQUw1SThsc0x0N21kcG5fSHRZNklZU3dvVTZ5QjJaMFk1c0Q5SERGTGZueDZKQ1otR1Rpdnl5MzRGMGdaV1p1bG9CZ2l6Q25IeWpxMlBnMVduWHZrdUZzUnFCV1lZejhmcXZGcmdsaVVGcTh0YzlldWlwOEhlOFlMTEhyTGxnblZzUlhOWHhrUklCbFBxX2FCN09PRndtX2JtY0tMdEpGT3c?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-09T15:36:43+00:00", "published_display": "09 Jul 2026 15:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor to exhibit blood volume analyzer at dysautonomia conference", "summary": "Daxor Corporation announced its first-time exhibition at the 14th Annual Dysautonomia International Conference to showcase its FDA-cleared Blood Volume Analyzer (BVA). The company anticipates significant sales growth, with revenue projected to increase over 400% in fiscal 2026 du", "url": "https://www.investing.com/news/company-news/daxor-to-exhibit-blood-volume-analyzer-at-dysautonomia-conference-93CH-4779143", "source_name": "Investing.com", "published_at": "2026-07-08T02:10:10", "published_display": "08 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor debuts Blood Volume Analyzer at dysautonomia conference", "summary": "Daxor Corporation (DXR) will exhibit its FDA-cleared, next-generation Blood Volume Analyzer (BVA) for the first time at the 14th Annual Dysautonomia International Conference in July 2026. The company aims to demonstrate how objective plasma and red blood cell volume data from the", "url": "https://www.stocktitan.net/news/DXR/daxor-corporation-announces-first-time-exhibition-at-the-14th-annual-k9dqq1p8mn48.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:10:10", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DXR - Daxor Corp Forecast, Target Price", "summary": "This article provides a detailed financial overview of Daxor Corp (DXR), including its last closing price, market capitalization, key financial ratios, and performance metrics. It lists various financial data points such as P/E, P/S, ROA, ROE, and percentage changes over differen", "url": "https://finviz.com/stock?t=DXR&ta=1&p=d&ty=fc&b=1", "source_name": "Finviz", "published_at": "2026-07-04T12:39:53", "published_display": "04 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DXR - Daxor Corp Earnings", "summary": "This article provides a detailed financial overview of Daxor Corp (DXR), including key metrics such as market capitalization, P/E ratio, sales, and employee data. It also covers performance indicators like EPS growth, insider and institutional ownership, and various profitability", "url": "https://finviz.com/quote?t=DXR&ta=1&p=d&ty=ea&b=1", "source_name": "Finviz", "published_at": "2026-07-03T05:10:57", "published_display": "03 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DXR - Daxor Corp Options", "summary": "This page provides a detailed financial overview of Daxor Corp (DXR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, performance metrics over different periods, and analyst r", "url": "https://finviz.com/stock?t=DXR&ty=oc&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-03T00:40:08", "published_display": "03 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation (DXR) Edges Higher, Testing Key Resistance Zone - Advance Decline Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbkF1cnIzQTNsMloyWXBwSGd5dUdISENDTE1HV1JPUFZkb3NEWHVIVGduWHdhNk84em92eXB2NXBnNmZwblBydTk3c25XdTl5ZmU4WGl4U25WM3VLZlRELXdKV2dvay1yRDdHNjBORFpnUkphbmt6ZkthRk1WX0VtYVU3aWp2ME0zalFYTUYySFVpbmZMS3preWpUSksxNnJWYmFMZ3lBZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T17:48:03+00:00", "published_display": "30 Jun 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) CFO receives 12,000-share stock grant, now holds 33,050", "summary": "Daxor Corp's CFO, Michel Robert J, received a compensation-related grant of 12,000 shares of Daxor Common Stock with no purchase price. These shares are scheduled to vest on June 23, 2026. Following this transaction, his direct holdings in the company's common stock total 33,050 ", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-13d649cdce7c.html", "source_name": "Stock Titan", "published_at": "2026-06-26T10:10:03", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Chief Scientific Officer receives 25,000-share stock grant", "summary": "Daxor's Chief Scientific Officer, Jonathan Adam Feldschuh, received a grant of 25,000 shares of Daxor common stock. This equity award, granted at $0.00 per share, increases his direct holdings to 78,908 shares. The granted shares are set to vest on June 23, 2026, indicating a com", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-7b32faf6c205.html", "source_name": "Stock Titan", "published_at": "2026-06-26T00:10:43", "published_display": "26 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Daxor Corp For: 25 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Daxor Corp, specifically for June 25th. The content is brief, primarily acting as a headline to direct readers to the filing details, and mentions the stock symbol DXR with a -2.91% performance. It also lists various ", "url": "https://za.investing.com/news/stock-market-news/form-4-daxor-corp-for-25-june-93CH-4344875", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T23:14:00", "published_display": "25 Jun 2026 23:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DAXOR (DXR) CEO receives 30,000-share equity grant, now holds 243,694", "summary": "DAXOR CORP CEO Michael Richard Feldschuh was granted 30,000 shares of Daxor Common Stock as compensation, vesting on June 23, 2026. This transaction, reported on Form 4, increased his direct holdings to 243,694 shares, with the granted shares valued at $0.00 each. This equity awa", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-56d8e5630450.html", "source_name": "Stock Titan", "published_at": "2026-06-25T23:09:44", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) director awarded 2,500 stock options at $10.14 strike", "summary": "Daxor Corp director Henry D. Cremisi was granted 2,500 stock options with an exercise price of $10.14 per share, expiring on June 23, 2031. This compensation award is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan and will ves", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-0c7aa1ab6569.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:41:28", "published_display": "25 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) director granted 2,500 stock options at $10.14", "summary": "Daxor Corp director Joy S. Goudie was granted 2,500 stock options with an exercise price of $10.14 per share, expiring on June 23, 2031. The options will vest in three annual installments from June 23, 2026, to June 23, 2028. This grant is contingent on SEC approval of an amendme", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-05cf88d02486.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:41:28", "published_display": "25 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DAXOR CORP (DXR) director receives 2,500 stock options at $10.14 strike", "summary": "DAXOR CORP director Edward Feuer was granted 2,500 stock options as compensation, with an exercise price of $10.14 per share and an expiration date of June 23, 2031. The grant is contingent on SEC approval to amend the Daxor Corporation 2020 Incentive Compensation Plan and will v", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-53be36eddcab.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:41:28", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DAXOR (DXR) director awarded 2,500 stock options at $10.14 strike price", "summary": "DAXOR CORP director Caleb DesRosiers was granted 2,500 stock options with an exercise price of $10.14 per share, vesting in three annual installments through June 23, 2028. This grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensati", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-1ea739a87caf.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:41:28", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (NASDAQ: DXR) investors reelect full board and ratify Bush & Associates as auditor", "summary": "Daxor Corporation (NASDAQ: DXR) shareholders reelected all six directors\u2014Henry D. Cremisi, Edward Feuer, Joy Goudie, Michael Feldschuh, Jonathan Feldschuh, and Caleb DesRosiers\u2014at their Annual Meeting held on June 23, 2026. Each director received robust support, with \"for\" votes ", "url": "https://www.stocktitan.net/sec-filings/DXR/8-k-daxor-corp-reports-material-event-5e2bbcab265d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:12", "published_display": "24 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation (DXR) Holds Near Support After Modest Decline - Quality Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQeEhac2NNVUx4aEtDbmtzbkxBS0RHUzJNSjNWWTZ4dnl5TkdWWk9SSk4xaVZ3VUVSMnZBR3JuUzlJbnM2emw5VEQ0U2FTbGlENGFzdUc1VS1Rc2pmcl9vY05LXy1ZbG1SUVQtanJwY1JBTWZXX2RrbTRzem84aVVjR09mLVdsSDNkeUJPd1EyMml0RnVnMHE4cmlVTFR6RzRTZ1lLMGxlM0Q?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Q4 2024 earnings summary", "summary": "Daxor (DXR) reported a strong Q4 2024, with net assets rising to $36.8M and revenue up 116.5% year-over-year. The company achieved cash flow break-even in Q1 2025 and expanded clinical adoption, while also investing in R&D and manufacturing. Daxor anticipates significant growth f", "url": "https://quartr.com/events/daxor-corp-dxr-q4-2024_FkIEOnaj", "source_name": "Quartr", "published_at": "2026-06-19T19:11:00", "published_display": "19 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Proxy Filing Summary", "summary": "Daxor (DXR) has scheduled its annual meeting for July 15, 2024, where shareholders will vote on electing six directors and ratifying Citrin Cooperman, LLP as the independent auditor for 2024. The Board recommends approving all director nominees and the auditor. Shareholders of re", "url": "https://quartr.com/events/daxor-corp-dxr-proxy-filing_FkIE5dbE", "source_name": "Quartr", "published_at": "2026-06-19T19:11:00", "published_display": "19 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Q4 2025 earnings summary", "summary": "Daxor (DXR) achieved a transformative 2025, marked by significant growth in its operating division and a substantial increase in total net assets to over $45.8 million, largely due to a strategic realignment and FDA 510(k) clearance for a new analyzer. The company saw a 45% year-", "url": "https://quartr.com/events/daxor-corp-dxr-q4-2025_FkIE5FGy", "source_name": "Quartr", "published_at": "2026-06-19T18:40:01", "published_display": "19 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 79, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Q2 2024 earnings summary", "summary": "Daxor (DXR) reported its Q2 2024 earnings, showing an increase in net assets year-over-year but a decrease from the end of 2023. The company experienced an improved net decrease in net assets from operations compared to the prior year, driven by higher sales of BVA system devices", "url": "https://quartr.com/events/daxor-corp-dxr-q2-2024_FkIEODaD", "source_name": "Quartr", "published_at": "2026-06-19T18:40:01", "published_display": "19 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This page provides historical dividend and stock split information for Daxor Corp (DXR). It indicates that Daxor Corp has distributed $0.00 in dividends over the past five years and currently shows no records of past stock splits. The page also includes current stock price data a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:11:00", "published_display": "18 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Daxor Corp (DXR), detailing its business segments and regional revenue and profit contributions. It notes that relevant financial data for these categories has not yet been disclosed by the company. The page also offer", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:32", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Daxor Corp (DXR), listing major individual and institutional holders. It highlights that Joseph Feldschuh UEO is the largest shareholder with 43.82%, followed by other Feldschuh family members. The report also provides a breakdown", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:32", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Daxor Corp's (DXR) institutional confidence, including its stock performance, key financial metrics, and a list of major shareholders. The data highlights significant institutional holdings and recent changes in shareholder act", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:34", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Daxor Corp (DXR), based on analysis from TradingKey. It highlights a target price of USD 22.50 with a 142.98% upside potential, derived from 2 analysts who largely recommend a \"Buy\" rating for the stock. Key financial data such as ma", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:10:34", "published_display": "17 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DXR - Daxor Corp Stock Price and Quote", "summary": "Daxor Corp (DXR) is a company specializing in medical instruments and supplies, particularly known for its BVA-100 Blood Volume Analyzer. The article provides a detailed overview of the company's financial performance, recent news releases highlighting new patents, product adopti", "url": "https://finviz.com/stock?t=DXR", "source_name": "Finviz", "published_at": "2026-06-04T14:40:09", "published_display": "04 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor", "summary": "Daxor Corporation announced it has received a U.S. patent for a \"Remote Blood Volume Monitor.\" This new technology allows for continuous, remote tracking of a patient's blood volume status using wearable sensors, such as smartwatches, complementing Daxor's existing baseline measu", "url": "https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/daxor-corporation-receives-us-patent-for-breakthrough-remote-blood-volume-monitor/2356789", "source_name": "The Manila Times", "published_at": "2026-06-04T02:39:20", "published_display": "04 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) plans June 23, 2026 vote on directors and auditor", "summary": "Daxor Corporation has scheduled its annual stockholder meeting for June 23, 2026, where shareholders will vote on electing six directors and ratifying Bush & Associates, CPA as the independent auditor for the 2026 fiscal year. The proxy statement details that as of May 20, 2026, ", "url": "https://www.stocktitan.net/sec-filings/DXR/def-14a-daxor-corp-definitive-proxy-statement-8dcc9d8ecb52.html", "source_name": "Stock Titan", "published_at": "2026-06-03T20:39:25", "published_display": "03 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Secures Patent for Innovative Blood Volume Monitoring Technology", "summary": "Daxor Corp (DXR) has secured a U.S. patent for an innovative system that enables remote monitoring of a patient's overall blood volume using non-invasive optical sensors, potentially integrated into wearable devices. This development is expected to improve patient care outcomes b", "url": "https://www.gurufocus.com/news/8896072/daxor-dxr-secures-patent-for-innovative-blood-volume-monitoring-technology?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-03T00:09:28", "published_display": "03 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Says Received US Patent for Remote Blood Volume Monitor Technology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/daxor-says-received-us-patent-123653756.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:36:53+00:00", "published_display": "02 Jun 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation (DXR) Holds Steady at $10.82 as Shares Test Key Support Zone - Cash Flow Strong Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQUTlYd01wN3RsRVFuZG85NmdqWW11YjRpVzU3aTRJejdmaEF3MXRrNms3UkJnV0RtNTQyNTZ6ZExVUE5qdlB6ajdJNEQ1T2tTOU9rMHVpdTNNQ2ZmS0J1MEwtS3BHb3pheXQtRmYxOW90ZUd5aWw3RElXNmh3ZWdkTWs4MlljVUMtMHBWTUhWX1lHTUFCTDhXUmNFV1BQM0tUaFhXMmZZNktFaWdta0lJVFhpbUJ6eDA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Leverages MedAxiom CV Transforum Spring\u201926 to Accelerate Commercial Adoption of Blood Volume Analysis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/daxor-leverages-medaxiom-cv-transforum-120000770.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T12:00:00+00:00", "published_display": "28 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation Announces FDA Clearance for Revolutionary Blood Volume Analyzer to Improve Patient Outcomes", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPcEpPYk1vbUtlb0poOEEyM1ZRcUxIWlgzLTBoQnRKTmRNUFFzemFRWV8zMVh1QVVUeV9PQVMxNWotZnNjc3RKU3pSRWhlLXRlUV9KaTltVXJRcU5WTUFvejJOSExRZDdBSUdQblJ4d2JkM09GZEtSZDZ0Sk84LTZZbUJTUFUwZEM5dTZiUGNxMW5LYnpPODMxX2ZYbldfRmxuMTB5VGkxOWdvVzVUYk9EVVNrMm1Yc1E0elh4MlRkTm8zLURpdG5vSGFvNmRiMlFUQlF3V2ZPN1U4UQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-08-07T07:00:00+00:00", "published_display": "07 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQNjZkWkltMERVQTM2T0ZIMW10OFgzWTJId3hvQS1XM2hmLTZEOE1HTS1HWkg4Ymd6SndFSll3OVN1dGs2RHVJamprNDdrUG0yRC00bHhrSkNHRTJIMlBCdmhJNWU1ZEJnNVlueFpGVE1RSUZscnc4bFRXUFBZanpDekotME4yQXpFS2RTZmlaUXRJRWVwVXJsU0tiVFBYUXdiLWZEUXEyYlkyWE1XNUhtNm9TUGVsc3cxdTJpZw?oc=5", "source_name": "Investing.com", "published_at": "2024-03-08T08:00:00+00:00", "published_display": "08 Mar 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPWUhyalVTQUw1SThsc0x0N21kcG5fSHRZNklZU3dvVTZ5QjJaMFk1c0Q5SERGTGZueDZKQ1otR1Rpdnl5MzRGMGdaV1p1bG9CZ2l6Q25IeWpxMlBnMVduWHZrdUZzUnFCV1lZejhmcXZGcmdsaVVGcTh0YzlldWlwOEhlOFlMTEhyTGxnblZzUlhOWHhrUklCbFBxX2FCN09PRndtX2JtY0tMdEpGT3c?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-09T15:36:43+00:00", "published_display": "09 Jul 2026 15:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor to exhibit blood volume analyzer at dysautonomia conference", "summary": "Daxor Corporation announced its first-time exhibition at the 14th Annual Dysautonomia International Conference to showcase its FDA-cleared Blood Volume Analyzer (BVA). The company anticipates significant sales growth, with revenue projected to increase over 400% in fiscal 2026 du", "url": "https://www.investing.com/news/company-news/daxor-to-exhibit-blood-volume-analyzer-at-dysautonomia-conference-93CH-4779143", "source_name": "Investing.com", "published_at": "2026-07-08T02:10:10", "published_display": "08 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor debuts Blood Volume Analyzer at dysautonomia conference", "summary": "Daxor Corporation (DXR) will exhibit its FDA-cleared, next-generation Blood Volume Analyzer (BVA) for the first time at the 14th Annual Dysautonomia International Conference in July 2026. The company aims to demonstrate how objective plasma and red blood cell volume data from the", "url": "https://www.stocktitan.net/news/DXR/daxor-corporation-announces-first-time-exhibition-at-the-14th-annual-k9dqq1p8mn48.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:10:10", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DXR - Daxor Corp Forecast, Target Price", "summary": "This article provides a detailed financial overview of Daxor Corp (DXR), including its last closing price, market capitalization, key financial ratios, and performance metrics. It lists various financial data points such as P/E, P/S, ROA, ROE, and percentage changes over differen", "url": "https://finviz.com/stock?t=DXR&ta=1&p=d&ty=fc&b=1", "source_name": "Finviz", "published_at": "2026-07-04T12:39:53", "published_display": "04 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DXR - Daxor Corp Earnings", "summary": "This article provides a detailed financial overview of Daxor Corp (DXR), including key metrics such as market capitalization, P/E ratio, sales, and employee data. It also covers performance indicators like EPS growth, insider and institutional ownership, and various profitability", "url": "https://finviz.com/quote?t=DXR&ta=1&p=d&ty=ea&b=1", "source_name": "Finviz", "published_at": "2026-07-03T05:10:57", "published_display": "03 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DXR - Daxor Corp Options", "summary": "This page provides a detailed financial overview of Daxor Corp (DXR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, performance metrics over different periods, and analyst r", "url": "https://finviz.com/stock?t=DXR&ty=oc&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-03T00:40:08", "published_display": "03 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation (DXR) Edges Higher, Testing Key Resistance Zone - Advance Decline Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbkF1cnIzQTNsMloyWXBwSGd5dUdISENDTE1HV1JPUFZkb3NEWHVIVGduWHdhNk84em92eXB2NXBnNmZwblBydTk3c25XdTl5ZmU4WGl4U25WM3VLZlRELXdKV2dvay1yRDdHNjBORFpnUkphbmt6ZkthRk1WX0VtYVU3aWp2ME0zalFYTUYySFVpbmZMS3preWpUSksxNnJWYmFMZ3lBZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T17:48:03+00:00", "published_display": "30 Jun 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) CFO receives 12,000-share stock grant, now holds 33,050", "summary": "Daxor Corp's CFO, Michel Robert J, received a compensation-related grant of 12,000 shares of Daxor Common Stock with no purchase price. These shares are scheduled to vest on June 23, 2026. Following this transaction, his direct holdings in the company's common stock total 33,050 ", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-13d649cdce7c.html", "source_name": "Stock Titan", "published_at": "2026-06-26T10:10:03", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Chief Scientific Officer receives 25,000-share stock grant", "summary": "Daxor's Chief Scientific Officer, Jonathan Adam Feldschuh, received a grant of 25,000 shares of Daxor common stock. This equity award, granted at $0.00 per share, increases his direct holdings to 78,908 shares. The granted shares are set to vest on June 23, 2026, indicating a com", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-7b32faf6c205.html", "source_name": "Stock Titan", "published_at": "2026-06-26T00:10:43", "published_display": "26 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Daxor Corp For: 25 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Daxor Corp, specifically for June 25th. The content is brief, primarily acting as a headline to direct readers to the filing details, and mentions the stock symbol DXR with a -2.91% performance. It also lists various ", "url": "https://za.investing.com/news/stock-market-news/form-4-daxor-corp-for-25-june-93CH-4344875", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T23:14:00", "published_display": "25 Jun 2026 23:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DAXOR (DXR) CEO receives 30,000-share equity grant, now holds 243,694", "summary": "DAXOR CORP CEO Michael Richard Feldschuh was granted 30,000 shares of Daxor Common Stock as compensation, vesting on June 23, 2026. This transaction, reported on Form 4, increased his direct holdings to 243,694 shares, with the granted shares valued at $0.00 each. This equity awa", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-56d8e5630450.html", "source_name": "Stock Titan", "published_at": "2026-06-25T23:09:44", "published_display": "25 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) director awarded 2,500 stock options at $10.14 strike", "summary": "Daxor Corp director Henry D. Cremisi was granted 2,500 stock options with an exercise price of $10.14 per share, expiring on June 23, 2031. This compensation award is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan and will ves", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-0c7aa1ab6569.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:41:28", "published_display": "25 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) director granted 2,500 stock options at $10.14", "summary": "Daxor Corp director Joy S. Goudie was granted 2,500 stock options with an exercise price of $10.14 per share, expiring on June 23, 2031. The options will vest in three annual installments from June 23, 2026, to June 23, 2028. This grant is contingent on SEC approval of an amendme", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-05cf88d02486.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:41:28", "published_display": "25 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DAXOR CORP (DXR) director receives 2,500 stock options at $10.14 strike", "summary": "DAXOR CORP director Edward Feuer was granted 2,500 stock options as compensation, with an exercise price of $10.14 per share and an expiration date of June 23, 2031. The grant is contingent on SEC approval to amend the Daxor Corporation 2020 Incentive Compensation Plan and will v", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-53be36eddcab.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:41:28", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DAXOR (DXR) director awarded 2,500 stock options at $10.14 strike price", "summary": "DAXOR CORP director Caleb DesRosiers was granted 2,500 stock options with an exercise price of $10.14 per share, vesting in three annual installments through June 23, 2028. This grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensati", "url": "https://www.stocktitan.net/sec-filings/DXR/form-4-daxor-corp-insider-trading-activity-1ea739a87caf.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:41:28", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (NASDAQ: DXR) investors reelect full board and ratify Bush & Associates as auditor", "summary": "Daxor Corporation (NASDAQ: DXR) shareholders reelected all six directors\u2014Henry D. Cremisi, Edward Feuer, Joy Goudie, Michael Feldschuh, Jonathan Feldschuh, and Caleb DesRosiers\u2014at their Annual Meeting held on June 23, 2026. Each director received robust support, with \"for\" votes ", "url": "https://www.stocktitan.net/sec-filings/DXR/8-k-daxor-corp-reports-material-event-5e2bbcab265d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:12", "published_display": "24 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation (DXR) Holds Near Support After Modest Decline - Quality Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQeEhac2NNVUx4aEtDbmtzbkxBS0RHUzJNSjNWWTZ4dnl5TkdWWk9SSk4xaVZ3VUVSMnZBR3JuUzlJbnM2emw5VEQ0U2FTbGlENGFzdUc1VS1Rc2pmcl9vY05LXy1ZbG1SUVQtanJwY1JBTWZXX2RrbTRzem84aVVjR09mLVdsSDNkeUJPd1EyMml0RnVnMHE4cmlVTFR6RzRTZ1lLMGxlM0Q?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Q4 2024 earnings summary", "summary": "Daxor (DXR) reported a strong Q4 2024, with net assets rising to $36.8M and revenue up 116.5% year-over-year. The company achieved cash flow break-even in Q1 2025 and expanded clinical adoption, while also investing in R&D and manufacturing. Daxor anticipates significant growth f", "url": "https://quartr.com/events/daxor-corp-dxr-q4-2024_FkIEOnaj", "source_name": "Quartr", "published_at": "2026-06-19T19:11:00", "published_display": "19 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Proxy Filing Summary", "summary": "Daxor (DXR) has scheduled its annual meeting for July 15, 2024, where shareholders will vote on electing six directors and ratifying Citrin Cooperman, LLP as the independent auditor for 2024. The Board recommends approving all director nominees and the auditor. Shareholders of re", "url": "https://quartr.com/events/daxor-corp-dxr-proxy-filing_FkIE5dbE", "source_name": "Quartr", "published_at": "2026-06-19T19:11:00", "published_display": "19 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Q4 2025 earnings summary", "summary": "Daxor (DXR) achieved a transformative 2025, marked by significant growth in its operating division and a substantial increase in total net assets to over $45.8 million, largely due to a strategic realignment and FDA 510(k) clearance for a new analyzer. The company saw a 45% year-", "url": "https://quartr.com/events/daxor-corp-dxr-q4-2025_FkIE5FGy", "source_name": "Quartr", "published_at": "2026-06-19T18:40:01", "published_display": "19 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 79, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Q2 2024 earnings summary", "summary": "Daxor (DXR) reported its Q2 2024 earnings, showing an increase in net assets year-over-year but a decrease from the end of 2023. The company experienced an improved net decrease in net assets from operations compared to the prior year, driven by higher sales of BVA system devices", "url": "https://quartr.com/events/daxor-corp-dxr-q2-2024_FkIEODaD", "source_name": "Quartr", "published_at": "2026-06-19T18:40:01", "published_display": "19 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This page provides historical dividend and stock split information for Daxor Corp (DXR). It indicates that Daxor Corp has distributed $0.00 in dividends over the past five years and currently shows no records of past stock splits. The page also includes current stock price data a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:11:00", "published_display": "18 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Daxor Corp (DXR), detailing its business segments and regional revenue and profit contributions. It notes that relevant financial data for these categories has not yet been disclosed by the company. The page also offer", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:32", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Daxor Corp (DXR), listing major individual and institutional holders. It highlights that Joseph Feldschuh UEO is the largest shareholder with 43.82%, followed by other Feldschuh family members. The report also provides a breakdown", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:32", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Daxor Corp's (DXR) institutional confidence, including its stock performance, key financial metrics, and a list of major shareholders. The data highlights significant institutional holdings and recent changes in shareholder act", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:34", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corp (DXR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Daxor Corp (DXR), based on analysis from TradingKey. It highlights a target price of USD 22.50 with a 142.98% upside potential, derived from 2 analysts who largely recommend a \"Buy\" rating for the stock. Key financial data such as ma", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dxr/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:10:34", "published_display": "17 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DXR - Daxor Corp Stock Price and Quote", "summary": "Daxor Corp (DXR) is a company specializing in medical instruments and supplies, particularly known for its BVA-100 Blood Volume Analyzer. The article provides a detailed overview of the company's financial performance, recent news releases highlighting new patents, product adopti", "url": "https://finviz.com/stock?t=DXR", "source_name": "Finviz", "published_at": "2026-06-04T14:40:09", "published_display": "04 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor", "summary": "Daxor Corporation announced it has received a U.S. patent for a \"Remote Blood Volume Monitor.\" This new technology allows for continuous, remote tracking of a patient's blood volume status using wearable sensors, such as smartwatches, complementing Daxor's existing baseline measu", "url": "https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/daxor-corporation-receives-us-patent-for-breakthrough-remote-blood-volume-monitor/2356789", "source_name": "The Manila Times", "published_at": "2026-06-04T02:39:20", "published_display": "04 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) plans June 23, 2026 vote on directors and auditor", "summary": "Daxor Corporation has scheduled its annual stockholder meeting for June 23, 2026, where shareholders will vote on electing six directors and ratifying Bush & Associates, CPA as the independent auditor for the 2026 fiscal year. The proxy statement details that as of May 20, 2026, ", "url": "https://www.stocktitan.net/sec-filings/DXR/def-14a-daxor-corp-definitive-proxy-statement-8dcc9d8ecb52.html", "source_name": "Stock Titan", "published_at": "2026-06-03T20:39:25", "published_display": "03 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor (DXR) Secures Patent for Innovative Blood Volume Monitoring Technology", "summary": "Daxor Corp (DXR) has secured a U.S. patent for an innovative system that enables remote monitoring of a patient's overall blood volume using non-invasive optical sensors, potentially integrated into wearable devices. This development is expected to improve patient care outcomes b", "url": "https://www.gurufocus.com/news/8896072/daxor-dxr-secures-patent-for-innovative-blood-volume-monitoring-technology?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-03T00:09:28", "published_display": "03 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Says Received US Patent for Remote Blood Volume Monitor Technology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/daxor-says-received-us-patent-123653756.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:36:53+00:00", "published_display": "02 Jun 2026 12:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation (DXR) Holds Steady at $10.82 as Shares Test Key Support Zone - Cash Flow Strong Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQUTlYd01wN3RsRVFuZG85NmdqWW11YjRpVzU3aTRJejdmaEF3MXRrNms3UkJnV0RtNTQyNTZ6ZExVUE5qdlB6ajdJNEQ1T2tTOU9rMHVpdTNNQ2ZmS0J1MEwtS3BHb3pheXQtRmYxOW90ZUd5aWw3RElXNmh3ZWdkTWs4MlljVUMtMHBWTUhWX1lHTUFCTDhXUmNFV1BQM0tUaFhXMmZZNktFaWdta0lJVFhpbUJ6eDA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Leverages MedAxiom CV Transforum Spring\u201926 to Accelerate Commercial Adoption of Blood Volume Analysis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/daxor-leverages-medaxiom-cv-transforum-120000770.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T12:00:00+00:00", "published_display": "28 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daxor Corporation Announces FDA Clearance for Revolutionary Blood Volume Analyzer to Improve Patient Outcomes", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPcEpPYk1vbUtlb0poOEEyM1ZRcUxIWlgzLTBoQnRKTmRNUFFzemFRWV8zMVh1QVVUeV9PQVMxNWotZnNjc3RKU3pSRWhlLXRlUV9KaTltVXJRcU5WTUFvejJOSExRZDdBSUdQblJ4d2JkM09GZEtSZDZ0Sk84LTZZbUJTUFUwZEM5dTZiUGNxMW5LYnpPODMxX2ZYbldfRmxuMTB5VGkxOWdvVzVUYk9EVVNrMm1Yc1E0elh4MlRkTm8zLURpdG5vSGFvNmRiMlFUQlF3V2ZPN1U4UQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-08-07T07:00:00+00:00", "published_display": "07 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQNjZkWkltMERVQTM2T0ZIMW10OFgzWTJId3hvQS1XM2hmLTZEOE1HTS1HWkg4Ymd6SndFSll3OVN1dGs2RHVJamprNDdrUG0yRC00bHhrSkNHRTJIMlBCdmhJNWU1ZEJnNVlueFpGVE1RSUZscnc4bFRXUFBZanpDekotME4yQXpFS2RTZmlaUXRJRWVwVXJsU0tiVFBYUXdiLWZEUXEyYlkyWE1XNUhtNm9TUGVsc3cxdTJpZw?oc=5", "source_name": "Investing.com", "published_at": "2024-03-08T08:00:00+00:00", "published_display": "08 Mar 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 79, "total_relevant": 35, "sentiment_summary": {"positive": 11, "negative": 1, "neutral": 23, "score": 58, "total": 35, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 10.53, "latest_week": "2026-07-10", "one_week_move": 1.4, "four_week_move": 13.7, "twelve_week_move": 5.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.127398, "market_dynamics_buy_signal": false, "relative_strength": -22.35258, "fair_value_gap": 8.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 51.4816, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.4% over one week, +13.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "TradingKey", "count": 5}, {"label": "Finviz", "count": 4}, {"label": "Quartr", "count": 4}, {"label": "dars.gov.et", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "\u5bcc\u9014\u725b\u725b", "count": 1}, {"label": "Investing.com South Africa", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 7}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.4% over one week, +13.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas"}], "updated_at": "2026-07-17T16:30:55.343681+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}